open access
Increased physiological [18F]FDG uptake in the liver and blood pool among patients with impaired renal function
, 1, 1, 1, 1, 1, 2, 1, 1, 1
Affiliations- Department of Radiology, Tokushima University, Tokushima City, Japan
- Department of Radiology, Nagoya University Hospital, Nagoya City, Japan
open access
Abstract
Background: In the daily clinical course, the liver uptake may seem to be increased in patients with renal failure. The purpose of this study was to investigate whether or not the FDG uptake of the liver, and the FDG uptake of blood pool which is generally used as a reference site as well as liver, is increased in patients with renal failure. Material and methods: We retrospectively analyzed 233 patients who underwent FDG positron emission tomography/computed tomography (PET/CT). Renal failure is defined as an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2. We compared the FDG uptake in the liver and mediastinal blood pool of 67 patients with impaired renal function to that in 166 patients with a normal renal function (eGFR ≥ 60 mL/min/1.73 m2). Correlations between the liver or mediastinal blood pool FDG uptake and the eGFR were also analyzed by Spearman’s correlation test. Results: Maximum and mean standardized uptake values (SUVmax and SUVmean, respectively) of the liver and the SUVmean of the mediastinal blood pool were 3.48 ± 0.57, 2.56 ± 0.37, and 1.90 ± 0.28 in the impaired renal function group, respectively, and 3.13 ± 0.45, 2.29 ± 0.33, and 1.66 ± 0.23, in the normal group, respectively. The SUVmax and SUVmean of the liver and SUVmean of the mediastinal blood pool in the impaired renal function group were significantly higher than those in the normal group (p < 0.001, < 0.001, and < 0.001, respectively). The SUVmax and SUVmean of the liver and SUVmean of the mediastinal blood pool of patients showed a significant negative correlation with the eGFR (Spearman’s p = –0.25, –0.30, and –0.40, respectively, each p < 0.001). Conclusions: FDG uptake in both the liver and mediastinal blood pool was higher in patients with impaired renal function.
Abstract
Background: In the daily clinical course, the liver uptake may seem to be increased in patients with renal failure. The purpose of this study was to investigate whether or not the FDG uptake of the liver, and the FDG uptake of blood pool which is generally used as a reference site as well as liver, is increased in patients with renal failure. Material and methods: We retrospectively analyzed 233 patients who underwent FDG positron emission tomography/computed tomography (PET/CT). Renal failure is defined as an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2. We compared the FDG uptake in the liver and mediastinal blood pool of 67 patients with impaired renal function to that in 166 patients with a normal renal function (eGFR ≥ 60 mL/min/1.73 m2). Correlations between the liver or mediastinal blood pool FDG uptake and the eGFR were also analyzed by Spearman’s correlation test. Results: Maximum and mean standardized uptake values (SUVmax and SUVmean, respectively) of the liver and the SUVmean of the mediastinal blood pool were 3.48 ± 0.57, 2.56 ± 0.37, and 1.90 ± 0.28 in the impaired renal function group, respectively, and 3.13 ± 0.45, 2.29 ± 0.33, and 1.66 ± 0.23, in the normal group, respectively. The SUVmax and SUVmean of the liver and SUVmean of the mediastinal blood pool in the impaired renal function group were significantly higher than those in the normal group (p < 0.001, < 0.001, and < 0.001, respectively). The SUVmax and SUVmean of the liver and SUVmean of the mediastinal blood pool of patients showed a significant negative correlation with the eGFR (Spearman’s p = –0.25, –0.30, and –0.40, respectively, each p < 0.001). Conclusions: FDG uptake in both the liver and mediastinal blood pool was higher in patients with impaired renal function.
Keywords
renal failure; eGFR; liver; mediastinal blood pool; FDG
About this articleTitle
Increased physiological [18F]FDG uptake in the liver and blood pool among patients with impaired renal function
Journal
Issue
Article type
Research paper
Pages
95-100
Published online
2022-07-12
Page views
4183
Article views/downloads
1363
DOI
Pubmed
Bibliographic record
Nucl. Med. Rev 2022;25(2):95-100.
Keywords
renal failure
eGFR
liver
mediastinal blood pool
FDG
Authors
Yoichi Otomi
Yuta Arai
Maki Otomo
Saho Irahara
Kaori Terazawa
Michiko Kubo
Takashi Abe
Takayoshi Shinya
Hideki Otsuka
Masafumi Harada
References (21)- Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med. 1991; 32(4): 623–648.
- Hawkins RA, Hoh CK. PET FDG studies in oncology. Nuclear Medicine and Biology. 1994; 21(5): 739–747.
- Hoh CK, Hawkins RA, Glaspy JA, et al. Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-D-glucose. J Comput Assist Tomogr. 1993; 17(4): 582–589.
- Ali SA, Amin DH, Abdelkhalek YI. Efficiency of whole-body 18F-FDG PET CT in detecting the cause of rising serum AFP level in post-therapeutic follow-up for HCC patients. Jpn J Radiol. 2020; 38(5): 472–479.
- Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med. 2009; 50 Suppl 1: 122S–50S.
- Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology. 1993; 189(3): 847–850.
- Meignan M, Gallamini A, Meignan M, et al. Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leuk Lymphoma. 2009; 50(8): 1257–1260.
- Barrington SF, Kluge R. FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas. Eur J Nucl Med Mol Imaging. 2017; 44(Suppl 1): 97–110.
- Zijlstra JM, Burggraaff CN, Kersten MJ, et al. FDG-PET as a biomarker for early response in diffuse large B-cell lymphoma as well as in Hodgkin lymphoma? Ready for implementation in clinical practice? Haematologica. 2016; 101(11): 1279–1283.
- Eknoya GE, Lameire N. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013; 3: 1–150.
- Furuya S, Manabe O, Ohira H, et al. Which is the proper reference tissue for measuring the change in FDG PET metabolic volume of cardiac sarcoidosis before and after steroid therapy? EJNMMI Res. 2018; 8(1): 94.
- Akers SR, Werner TJ, Rubello D, et al. 18F-FDG uptake and clearance in patients with compromised renal function. Nucl Med Commun. 2016; 37(8): 825–832.
- Kode V, Karsch H, Osman MM, et al. Impact of Renal Failure on F18-FDG PET/CT Scans. Front Oncol. 2017; 7: 155.
- Minamimoto R, Takahashi N, Inoue T. FDG-PET of patients with suspected renal failure: standardized uptake values in normal tissues. Ann Nucl Med. 2007; 21(4): 217–222.
- Ziai P, Hayeri MR, Salei A, et al. Role of optimal quantification of FDG PET imaging in the clinical practice of radiology. Radiographics. 2016; 36(2): 481–496.
- Ambrosini V, Fanti S, Chengazi VU, et al. Diagnostic accuracy of FDG PET/CT in mediastinal lymph nodes from lung cancer. Eur J Radiol. 2014; 83(8): 1301–1302.
- Abele JT, Fung CI. Effect of hepatic steatosis on liver FDG uptake measured in mean standard uptake values. Radiology. 2010; 254(3): 917–924.
- Keramida G, Potts J, Bush J, et al. Accumulation of (18)F-FDG in the liver in hepatic steatosis. AJR Am J Roentgenol. 2014; 203(3): 643–648.
- Liu G, Li Y, Hu P, et al. The combined effects of serum lipids, BMI, and fatty liver on 18F-FDG uptake in the liver in a large population from China: an 18F-FDG-PET/CT study. Nucl Med Commun. 2015; 36(7): 709–716.
- Sarikaya I, Sarikaya A, Sharma P. Assessing the effect of various blood glucose levels on F-FDG activity in the brain, liver, and blood pool. J Nucl Med Technol. 2019; 47(4): 313–318.
- Otomi Y, Otsuka H, Terazawa K, et al. A reduced liver F-FDG uptake may be related to hypoalbuminemia in patients with malnutrition. Ann Nucl Med. 2019; 33(9): 689–696.
